Evaluating expected costs and benefits of granting access to new treatments on the basis of progression-free survival in non-small-cell lung cancer

JAMA Oncology

Volumn 1, Issue 2, 2015, Pages 196-202

  Lakdawalla, Darius N ^a   Chou, Jacquelyn W ^b   Linthicum, Mark T ^b   MacEwan, Joanna P ^b   Zhang, Jie ^c   Goldman, Dana P ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b PRECISION HEALTH ECONOMICS   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOMA, NON-SMALL-CELL LUNG; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DISEASE FREE SURVIVAL; ECONOMICS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN; LUNG NEOPLASMS; MANAGEMENT; MORTALITY; ORGANIZATION AND MANAGEMENT; PATIENT SELECTION; PROBABILITY; STATISTICAL MODEL; SURVIVAL; TIME; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DISEASE-FREE SURVIVAL; ELIGIBILITY DETERMINATION; HEALTH CARE COSTS; HEALTH SERVICES ACCESSIBILITY; HUMANS; LUNG NEOPLASMS; MODELS, ECONOMIC; PATIENT SELECTION; POLICY MAKING; PROBABILITY; PROCESS ASSESSMENT (HEALTH CARE); SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84965094890     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.0203     Document Type: Article

References (28)

1. Baird LG, Banken R, Eichler HG, et al. Accelerated access to innovative medicines for patients in need. Clin Pharmacol Ther. 2014;96(5):559-571.
2. US Department of Health and Human Services. Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research; 2007. http://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf. Accessed February 9, 2015.
3. Beckman M. More clinical cancer treatments judged by progression-free rather than overall survival. J Natl Cancer Inst. 2007;99(14):1068-1069.
4. McKee AE, Farrell AT, Pazdur R, Woodcock J. The role of the US Food and Drug Administration review process: clinical trial endpoints in oncology. Oncologist. 2010;15(suppl 1):13-18.
5. Sherrill B, Kaye JA, Sandin R, Cappelleri JC, Chen C. Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology. Onco Targets Ther. 2012;5:287-296.
6. Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol. 2007;25(33):5218-5224.
7. Buyse M, Squifflet P, Laporte S, et al. Prediction of survival benefits from progression-free survival in patients with advanced non small cell lung cancer: evidence from a pooled analysis of 2,838 patients randomized in 7 trials. J Clin Oncol. 2008;26(15S):8019.
8. Hotta K, Fujiwara Y, Matsuo K, et al. Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2009;4(3):311-317.
9. Knox JJ. Progression-free survival as endpoint in metastatic RCC? Lancet. 2008;372(9637):427-429.
10. Lakdawalla DN, Sun EC, Jena AB, Reyes CM, Goldman DP, Philipson TJ. An economic evaluation of the war on cancer. J Health Econ. 2010;29(3):333-346.
11. Gong Q, Fang L. Asymptotic properties of mean survival estimate based on the Kaplan-Meier curve with an extrapolated tail. Pharm Stat. 2012;11(2):135-140.
12. American Cancer Society. Cancer Facts & Figures 2015. Atlanta, GA: American Cancer Society; 2015.
13. National Cancer Institute. 250 Years of Advances Against Cancer. 2014. http://www.cancer.gov/researchandfunding/progress/250-years-advances. Accessed February 9, 2015.
14. Sechler M, Cizmic AD, Avasarala S, et al. Non-small-cell lung cancer: molecular targeted therapy and personalized medicine-drug resistance, mechanisms, and strategies. Pharmgenomics Pers Med. 2013;6:25-36.
15. Stevens W, Philipson T, Wu Y, Chen C, Lakdawalla D. A cost-benefit analysis of using evidence of effectiveness in terms of progression free survival in making reimbursement decisions on new cancer therapies. Forum Health Econ Policy. 2014;17(1):21-52.
16. Murphy KM, Topel RH. The value of health and longevity. J Polit Econ. 2006;114(5):871-904.
17. Rosen S. The value of changes in life expectancy. J Risk Uncertain. 1988;1(3):285-304.
18. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163(14):1637-1641.
19. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3):332-342.
20. Aldy JE, Viscusi WK. Adjusting the value of a statistical life for age and cohort effects. Rev Econ Stat. 2008;90(3):573-581.
21. Seabury SA, Goldman DP, Maclean JR, Penrod JR, Lakdawalla DN. Patients value metastatic cancer therapy more highly than is typically shown through traditional estimates. Health Aff (Millwood). 2012;31(4):691-699.
22. Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist. 2006;11(2):90-95.
23. Bajaj PS, Veenstra DL, Goertz HP, Carlson JJ. Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis. J Med Econ. 2014;17(8):538-546.
24. Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, Veenstra DL. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer. 2008;61(3):405-415.
25. Klein R, Wielage R, Muehlenbein C, et al. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol.2010;5(8):1263-1272.
26. Shah M, Winfree KB, Peterson P, Gruschkus SK, Eaddy M, Green MR. Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.Lung Cancer. 2013;82(1):121-127.
27. Vera-Badillo FE, Shapiro R, Ocana A, Amir E, Tannock IF. Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol. 2013;24(5):1238-1244.
28. US Food and Drug Administration. Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Silver Spring, MD: US Food and Drug Administration; 2007. http://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf. Accessed January 6, 2015.